Clinical Trials Logo

Gastroesophageal Reflux clinical trials

View clinical trials related to Gastroesophageal Reflux.

Filter by:

NCT ID: NCT02620241 Completed - Clinical trials for Gastro-oesophageal Reflux

Influence of Intrapulmonary Percussive Ventilation (IPV) on Gastro-oesophageal Reflux (GOR).

Start date: October 2015
Phase: N/A
Study type: Interventional

The study evaluates the effect on gastro-oesophageal reflux (GOR) of infants sitting in a stable upright position during 20 min. This is an addendum to the previous study with record number clinical trials.gov NCT02124863

NCT ID: NCT02619747 Terminated - Clinical trials for Gastro-esophageal Reflux Disease (GERD)

Compound Sodium Alginate Oral Suspension Sachet 4-hour Esophageal pH Study in GERD Patients

Start date: April 2014
Phase: Phase 3
Study type: Interventional

Multi-centre, randomised, open-label, placebo-controlled, two-period crossover study of 4 hour pH monitoring following a refluxogenic meal and drink.

NCT ID: NCT02618044 Completed - Obesity Clinical Trials

Laparoscopic Roux-en-Y Gastric Bypass and Gastro-esophageal Reflux

Start date: May 2006
Phase: N/A
Study type: Observational

Laparoscopic Roux-en-Y Gastric Bypass (LRYGB) is considered the weight loss procedure of choice for patients suffering of gastro-esophageal reflux (GER). However, long term instrumental evaluations of GER after LRYGB are not available. The aim of this study is to evaluate the long-term effects of laparoscopic Roux-en-Y Gastric Bypass (LRYGB) on gastro-esophageal function.

NCT ID: NCT02616302 Recruiting - Clinical trials for Gastroesophageal Reflux Disease (GERD)

A Study of Dexlansoprazole Delayed-Release Capsules to Treat Symptomatic Nonerosive Gastroesophageal Reflux Disease in Children

Start date: February 20, 2023
Phase: Phase 2
Study type: Interventional

The main aims of the study are to see the - side effects of Dexlansoprazole treatment - effectiveness of Dexlansoprazole treatment in children having symptomatic nonerosive gastroesophageal reflux disease (GERD). Participants will take Dexlansoprazole by mouth once daily for 12 weeks

NCT ID: NCT02609620 Not yet recruiting - Clinical trials for Gastro-esophageal Reflux

Safety & Initial Efficacy of the LunGuard PFT Sys. on Enteral-Fed, Sedated and Mechanically Ventilated Patients Peristaltic Feeding Tube

PFT
Start date: December 2015
Phase: N/A
Study type: Interventional

This study is designated to test the safety and initial efficacy of the LunGuard's PFT device for reduction of GER. Enterally-Fed, Sedated and Mechanically Ventilated Critically Ill Patients in the ICU will have the PFT positioned in them and used for feeding of a Nutritional Formula.Samples will be taken by suction on predetermined intervals and analysed for Pepsin A concentration. The PFT will be removed upon completion of the study's scheduled routine. Patients in the control group will have a standard polyurethane nasogastric device inserted according to standard procedure, which is considered the gold standard.

NCT ID: NCT02606851 Completed - Clinical trials for Patients With Typical Symptoms of GERD (GERD Q >= 8)

Proton Pump Inhibitor Empirical Treatment in Management of Outpatients With Gastroesophageal Reflux Disease.

Start date: December 4, 2015
Phase: N/A
Study type: Observational

China Survey of Proton Pump Inhibitor Empirical Treatment in Management of Outpatients with Gastroesophageal Reflux Disease

NCT ID: NCT02592902 Completed - Clinical trials for Recurrent Respiratory Papillomatosis

Recurrent Respiratory Papillomatosis and Extraesophageal Reflux

Start date: April 2014
Phase: N/A
Study type: Interventional

The purpose of the study was to determine, whether patients with recurrent respiratory papillomatosis (RRP) suffer from extra oesophageal reflux more often than patients with laryngeal cyst (control group).

NCT ID: NCT02587910 Recruiting - GERD Clinical Trials

Melanole, a Dietary Supplement, for the Treatment of Gastroesophageal Reflux Disease

GERDMeDS
Start date: October 2015
Phase: Phase 2/Phase 3
Study type: Interventional

Melanole, a Nigella sativa (Black Seed) extract , is studied for the treatment of GERD. Participants, who meet the inclusion criteria, will be divided into two arms. Arm 1: Subjects who meet criteria for GERD will undergo 24 hour pH monitoring. Arm 2: Subjects who meet criteria for GERD and who undergo only symptomatic monitoring of GERD on treatment. All participants will be evaluated before and after the administration of the study product.

NCT ID: NCT02584751 Recruiting - Clinical trials for Gastro Esophageal Reflux Disorder

GERD and Anti-Reflux Therapy Between Able-bodied and SCI Individuals

Start date: August 2016
Phase: Phase 1
Study type: Interventional

Respiratory dysfunction, esophageal dysmotility, and a gastroesophageal reflux disease (GERD) have been demonstrated to be highly prevalent in persons with SCI. GERD has been linked to respiratory symptoms and conditions such as asthma, chronic cough, and an increased rate of respiratory infections in the general population. In persons with asthma, respiratory symptoms and dependency on asthma medications have been reduced by treatment with anti-reflux medication. Possible mechanisms have been proposed for this link, including the microaspiration of reflux materials, which may result in airway acidification and aspiration pneumonia, or the stimulation of the vagus nerve through acid-sensitive receptors in the esophagus with associated esophageal inflammation and reflex bronchoconstriction. Investigators propose to study the effects of anti-reflux therapy (proton pump inhibition) in persons with SCI on objective and subjective symptoms of respiratory function to determine the underlying mechanisms of airway inflammation due to GERD.

NCT ID: NCT02579460 Completed - Clinical trials for Gastroesophageal Reflux Disease

Reflux-Induced Oxidative Stress in Barrett's Esophagus: Response, Repair, and Epithelial-Mesenchymal-Transition

Start date: November 2015
Phase: N/A
Study type: Interventional

The purpose of this study is to elucidate mechanisms whereby oxidative stress induced by acute reflux esophagitis: 1) activates p38 to regulate proteins that control the G1/S cell cycle checkpoint, and 2) activates HIFs (hypoxia inducible factors) to cause autocrine VEGF (vascular endothelial growth factor) signaling that triggers the EMT (epithelial-mesenchymal-transition) program in Barrett's esophagus.